The global structural biology & molecular modeling techniques market accounted for USD 2.52 billion in 2015 and is expected to grow at a CAGR of 18.2% over the coming years. The market is predominantly driven by rise in the prevalence of chronic diseases with acquired drug resistance that exemplifies the need for new and advanced therapeutics.
This has resulted in the high clinical urgency to incorporate structural biology & molecular modeling techniques to develop a new generation of drugs. For instance, in 2011, researchers from the University of Natural Resources and Life Sciences in Austria carried out molecular dynamics simulations to study the activity of humanized antibodies (Ab2/3H6), which is believed to neutralize HIV-1. The results generated through this simulation successfully identified back mutation sites in antibodies to enable antibody immunization without the loss of specificity and binding affinity in them.
U.S. structural biology & molecular modeling techniques market, by tools, 2014 - 2025 (USD Million)
In addition, the high drug attrition rate associated with late-phase clinical trials in drug development is a significant contributor of the elevated costs, which is further presumed to propel the demand for modeling techniques to reduce the probability of drug failure. This is achieved through the utilization of prediction software that provides detailed insights of proteins with 3-D molecular structures and predicts their binding conformation & biological interactions.
The emergence of technological innovations has led to the development of validated mathematical models that enable the determination of accurate structures and predict cellular functions & interactions, which aid in the identification of novel leads with greater chances. For instance, potency determination of new drug molecules through in silico screening of 3-D chemical structures expedite the lead discovery and optimization process, thereby allowing greater focus to be laid on targets with high therapeutic potential.
Moreover, advancements in, in silico drug designing tools coupled with the implementation of a multidisciplinary approach involving, computational biology, molecular biology, and biophysics, are resulting in novel methods that facilitate structural biologists in understanding diverse protein sequences and predicting protein structures accurately. These novel solutions are believed to enhance biomedical research and help address challenges, thereby optimizing the drug discovery process and boosting the demand for modeling tools.
In 2015, SaaS & standalone modeling software accounted for the largest share of the tools segment. The substantial share attained by this segment is believed to be a consequence of the increasing number of computer-aided predictive procedures in structural biology that are to serve the market with significant growth opportunities during the forecast period.
In addition, assistance of sophisticated molecular modeling software has led to consistent development in research; hence wide-ranging applications in varied medical disciplines are presenting greater opportunities for this sector. Furthermore, growing adoption of this software by research professionals to analyze dock libraries and protein homology is expected to positively reinforce market growth during the forecast period.
Drug discovery is expected to witness a lucrative CAGR during the forecast period. This unprecedented growth rate can be attributed to the associated benefits of molecular modeling in drug discovery. The benefits facilitate researchers and structural biologists to identify critical gaps that restrict the drug discovery process, thereby yielding a relatively reduced drug attrition rate.
The high potential growth prospects can be attributed to probable incorporation of structural biology & molecular modeling techniques in pharmacogenetics and pharmacogenomics, contributing toward growth of the drug discovery segment. In addition, high clinical urgency to develop drugs for their use in conditions, such as pregnancy, where several drugs cannot be administered, is one of the key growth factors presumed to drive the segment. Moreover, rising number of structural prediction models to study physiological and biochemical changes are anticipated to provide a high potential growth platform to the market.
In 2015, North America captured a dominant share of the overall structural biology & molecular modeling techniques market. Several collaborations undertaken by prominent market players toward heightening their R&D capabilities to ensure high medical standards is expected to propel the demand in this region. For instance, the American Diabetes Association introduced a research forum in collaboration with Entelos, Inc. to develop new treatment alternatives for Type 1 Diabetes through drug development simulation processes.
Global structural biology & molecular modeling techniques market share, by application, 2015
The Asia Pacific structural biology & molecular modeling techniques is expected to witness the fastest CAGR during the forecast period owing to the rising presence of contract research organizations, increasing healthcare IT spending, and unprecedented evolution of the healthcare infrastructure and standards.
This industry is predicted to exhibit intense competition over the coming years due to the increasing adoption of collaborative strategies amongst the market players to sustain in the competition. The other strategies incorporated are computational advancements in software, mergers & acquisitions, and agreements for drug development.
For instance, In January 2015, Chemical Computing Group released an updated version of its protein structure database, PSILO. The enhanced features included a redesigned web interface and easy access to a vast repository of protein structures. Also, in May 2014, Dassault Systèmes announced the launch of BIOVIA, which is focused on enabling biological, chemical, materials designing, and molecular simulations as well as open collaborative research and quality management.
Attribute |
Details |
Base year for estimation |
2015 |
Actual estimates/Historical data |
2014 - 2015 |
Forecast period |
2016 - 2025 |
Market representation |
Revenue in USD Million & CAGR from 2016 to 2025 |
Regional scope |
North America, Europe, Asia-Pacific, Latin America & MEA |
Country scope |
U.S., Canada, UK, Germany, Japan, China, Brazil, Mexico, South Africa |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors and trends |
15% free customization scope (equivalent to 5 analyst working days) |
If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization |
This report forecasts revenue growth and provides an analysis of the industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the structural biology & molecular modeling techniques market on the basis of tools, application, and region:
Tools Outlook (Revenue, USD Million, 2014 - 2025)
SaaS & standalone modeling
Homology modeling
Threading
Molecular dynamics
Ab Initio
Hybrid
Others
Visualization & analysis
Databases
Others
Application Outlook (Revenue, USD Million, 2014 - 2025)
Drug development
Drug discovery
Others
Regional Outlook (Revenue, USD Million, 2014 - 2025)
North America
U.S
Canada
Europe
Germany
UK
Asia Pacific
Japan
China
India
Latin America
Brazil
Mexico
The Middle East and Africa
South Africa
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
ISO Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.